Department of Pharmacology, Physiology & Neuroscience, Rutgers-New Jersey Medical School, Cancer Institute of New Jersey, Newark, NJ, 07101, USA.
Department of Microbiology, Biochemistry & Molecular Genetics, Rutgers-New Jersey Medical School, Cancer Institute of New Jersey, Newark, NJ, 07101, USA.
Breast Cancer Res. 2018 Nov 20;20(1):138. doi: 10.1186/s13058-018-1063-2.
Early analyses of human breast cancer identified high expression of the insulin-like growth factor type 1 receptor (IGF-1R) correlated with hormone receptor positive breast cancer and associated with a favorable prognosis, whereas low expression of IGF-1R correlated with triple negative breast cancer (TNBC). We previously demonstrated that the IGF-1R acts as a tumor and metastasis suppressor in the Wnt1 mouse model of TNBC. The mechanisms for how reduced IGF-1R contributes to TNBC phenotypes is unknown.
We analyzed the METABRIC dataset to further stratify IGF-1R expression with patient survival and specific parameters of TNBC. To investigate molecular events associated with the loss of IGF-1R function in breast tumor cells, we inhibited IGF-1R in human cell lines using an IGF-1R blocking antibody and analyzed MMTV-Wnt1-mediated mouse tumors with reduced IGF-1R function through expression of a dominant-negative transgene.
Our analysis of the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset revealed association between low IGF-1R and reduced overall patient survival. IGF-1R expression was inversely correlated with patient survival even within hormone receptor-positive breast cancers, indicating reduced overall patient survival with low IGF-1R was not due simply to low IGF-1R expression within TNBCs. Inhibiting IGF-1R in either mouse or human tumor epithelial cells increased reactive oxygen species (ROS) production and activation of the endoplasmic reticulum stress response. IGF-1R inhibition in tumor epithelial cells elevated interleukin (IL)-6 and C-C motif chemokine ligand 2 (CCL2) expression, which was reversed by ROS scavenging. Moreover, the Wnt1/dnIGF-1R primary tumors displayed a tumor-promoting immune phenotype. The increased CCL2 promoted an influx of CD11b monocytes into the primary tumor that also had increased matrix metalloproteinase (MMP)-2, MMP-3, and MMP-9 expression. Increased MMP activity in the tumor stroma was associated with enhanced matrix remodeling and collagen deposition. Further analysis of the METABRIC dataset revealed an increase in IL-6, CCL2, and MMP-9 expression in patients with low IGF-1R, consistent with our mouse tumor model and data in human breast cancer cell lines.
Our data support the hypothesis that reduction of IGF-1R function increases cellular stress and cytokine production to promote an aggressive tumor microenvironment through infiltration of immune cells and matrix remodeling.
早期对人类乳腺癌的分析表明,胰岛素样生长因子 1 型受体(IGF-1R)的高表达与激素受体阳性乳腺癌相关,并且与预后良好相关,而 IGF-1R 的低表达与三阴性乳腺癌(TNBC)相关。我们之前证明,IGF-1R 在 Wnt1 小鼠 TNBC 模型中作为肿瘤和转移抑制因子发挥作用。减少 IGF-1R 如何导致 TNBC 表型的机制尚不清楚。
我们分析了 METABRIC 数据集,以进一步根据患者生存和 TNBC 的特定参数对 IGF-1R 的表达进行分层。为了研究与乳腺癌细胞中 IGF-1R 功能丧失相关的分子事件,我们使用 IGF-1R 阻断抗体抑制人细胞系中的 IGF-1R,并通过表达显性负转录物分析具有降低 IGF-1R 功能的 MMTV-Wnt1 介导的小鼠肿瘤。
我们对乳腺癌国际联合会(METABRIC)数据集的分子分类分析表明,低 IGF-1R 与患者总生存率降低之间存在关联。即使在激素受体阳性乳腺癌中,IGF-1R 的表达也与患者的生存呈负相关,这表明低 IGF-1R 导致的总患者生存率降低并不是由于 TNBC 中 IGF-1R 的低表达所致。在小鼠或人类肿瘤上皮细胞中抑制 IGF-1R 会增加活性氧(ROS)的产生并激活内质网应激反应。在肿瘤上皮细胞中抑制 IGF-1R 会升高白细胞介素(IL)-6 和 C-C 基序趋化因子配体 2(CCL2)的表达,而 ROS 清除可逆转该表达。此外,Wnt1/dnIGF-1R 原代肿瘤表现出促进肿瘤的免疫表型。增加的 CCL2 促进了 CD11b 单核细胞进入原代肿瘤,该肿瘤的基质金属蛋白酶(MMP)-2、MMP-3 和 MMP-9 表达也增加。肿瘤基质中 MMP 活性的增加与基质重塑和胶原蛋白沉积有关。对 METABRIC 数据集的进一步分析表明,低 IGF-1R 患者的 IL-6、CCL2 和 MMP-9 表达增加,与我们的小鼠肿瘤模型和人类乳腺癌细胞系的数据一致。
我们的数据支持这样的假设,即 IGF-1R 功能的降低会增加细胞应激和细胞因子的产生,从而通过免疫细胞浸润和基质重塑促进侵袭性肿瘤微环境。